On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

HIMS accelerates its global push with the ZAVA acquisition and a planned Canada launch targeting affordable obesity care.

Shark attack survivor Paul de Gelder joins us to talk Navy diving, bull sharks, and his wild return in Air Jaws and more ...

Hims & Hers Health recurring revenue grew 111% YoY, boosted by personalization and chronic care. Forecasting $2.35B revenue ...

Morningstar analyst Nicolas Owens breaks down airline earnings, as Delta restores its guidance and signals a clearer outlook ...

Daniel Jones being gone is the main source of hope? 6:45 Layers of the current QB room 15:15 What if Aaron Rodgers or Matthew ...

Analysts have provided Laboratory Corp with 8 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $276.5, suggesting a potential 9.69% upside.

The company will offer a generic version of semaglutide in the country after Novo Nordisk let its patent expire there. Hims & ...

You’ve been losing weight, and the finish line is in sight. Or maybe you’ve already hit your goal weight. What do you do when you get there? Should you keep taking your oral weight loss medication?

The overall sentiment of these big-money traders is split between 31% bullish and 50%, bearish. Out of all of the special options we uncovered, 3 are puts, for a total amount of $106,898, and 13 are ...

The BUZZ Index returned 12.68% during the month of June compared to a return of 5.09% for the S&P 500 Index during the same ...